Bone Demineralization in Postmenopausal Women: Role of Anamnestic Risk Factors

Table 4

Summary of the principal characteristics of the main studies exploring the effects of the treatment with L-thyroxin on the bone mineral density (BMD).

Authors	Thyroid disease	Number of patients	Type of treatment	Length of treatment (years)	Menopausal status	Effect on BMD
Affinito et al., 1996 [12]	Hypothyroidism	54	Suppressive	Various	After	Decreased
Baldini et al., 2002 [13]	Nontoxic goiter	43	Suppressive	≥2	Before and after	Unchanged
Chen et al., 2004 [14]	Cancer (thyroidectomy)	69	Suppressive	7.3±3	44 before; 25 after	Decreased
	Nodular goiter	32	None	NA		None
Foldes et al., 1993 [15]	Subclinical hyperthyroidism	37	None	NA	Before and after	None
	Toxic adenoma	22	None	NA		Decreased in postmenopausal
Gorres et al., 1996 [16]	Cancer (thyroidectomy)	65	Suppressive		15 before; 32 after; 18 men	Unchanged
Hadji et al., 2000 [17]	Nontoxic goiter and hypothyroidism	156	Substitutive	>5	Before and after	Slightly decreased
Heijckmann et al., 2005 [18]	Cancer	59	Suppressive	>6		Unchanged
Kung and Yeung, 1996 [19]	Cancer (thyroidectomy)	46	Suppressive	2	After	Decreased
Larijani et al., 2004 [20]	Thyroid nodules	41	Substitutive	>1	Before	Unchanged
Mikosch et al., 2001 [21]	Cancer	98	Suppressive			Unchanged
Nuzzo et al., 1998 [22]	Nontoxic goiter	40	Suppressive	1.5–14	Before	Unchanged
Sijanovic and Karner, 2001 [23]	Cancer (thyroidectomy)	19	Suppressive	9	Before	Decreased
Toivonen et al., 1998 [24]	Cancer (thyroidectomy)	29	Suppressive	9–11	25 women; 4 men	Decreased

NA: not applicable.